HOME >> BIOLOGY >> NEWS
Improved NIST SRM aids lead poisoning detection

od obtained from goats. The red blood cell system of an adult goat is much closer to that of a human, making it a better model for assessing proficiency for erythrocyte protoporphyrin, a biomarker of lead exposure. NISTs partner in developing 955c, the New York State Department of Healths Wadsworth Center Lead Poisoning Laboratory, dosed adult goats with lead acetate to produce blood pools containing lead physiologically bound to red blood cells.* The new SRM provides a better match than its predecessor to the blood samples clinicians analyze. The lead concentrations were determined by NIST using highly specialized methodology that resulted in high accuracy and low measurement uncertainty.

The changing goal line for blood lead concentration makes SRM 955c especially useful to laboratories. The lowest lead concentration level in the previous standard was 4 micrograms per deciliter or 40 parts per billion. In contrast, the lowest lead concentration level of SRM 955c is 0.4 microgram per deciliter or four parts per billion, the level of lead in an undosed animal. It is intended to represent the natural level of lead in an unexposed human population (although it is not yet known if any lead is naturally present in human blood). The lowest concentration in the SRM is 25 times lower than the DHHS 2010 goal, and will enable the development of next generation clinical methods that will be needed to accurately measure blood lead levels in children as progress is made toward eliminating lead exposure.

In addition to lead, levels two through four of SRM 955c contain added amounts of arsenic, cadmium, mercury, methylmercury and ethylmercury to facilitate future efforts to develop clinical methods to measure these toxins in human blood. At present, NIST provides information values only for the concentrations of cadmium and total mercury (including methylmercury and ethylmercury.) As values become available for arsenic, methylmercury and ethylmercury, the cert
'"/>

Contact: John Blair
john.blair@nist.gov
301-975-4261
National Institute of Standards and Technology (NIST)
3-Aug-2007


Page: 1 2 3

Related biology news :

1. Improved predictions of warming-induced extinctions sought
2. Improved imaging for identifying breast cancer in overweight women
3. Improved speech without vocal cords
4. Improved blood safety measures from Pall can increase platelet availability
5. Improved statistical tools reveal many linked loci
6. Improved process of drying lumber may save millions
7. Improved cancer treatments aim of new biology research program
8. Improved recipe for magnetic brain stimulation
9. Improved molecular switch could serve as sensor, medical tool
10. Leading the fight against food poisoning
11. Dipstick test could reduce risk of food poisoning by rapidly detecting spoilage

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Improved NIST SRM aids lead poisoning detection

(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
(Date:4/27/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® Smart ... week of May, 2015 and will be fulfilling all ... Gino Pereira , Chief Executive Officer said, ... Wocket® enters the consumer market. We would like to ...
(Date:4/21/2015)... 2015 High crime rate, ... boosting access control systems market in Saudi ... recently published report by TechSci Research " Saudi Arabia Access ... control systems market in Saudi Arabia ... access control systems market in the Kingdom is growing ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
(Date:5/21/2015)... , May 21, 2015  Prima Biomed Ltd. ... that is striving to become a leader in the ... recently announced that the final CVac data from the ... a clear trend for a clinically meaningful improvement in ... second remission patients. In the group of ...
(Date:5/21/2015)... 21, 2015 Imagine being able ... and those of others. Being able to read faces ... read people to anticipate their thoughts and actions like ... and feelings to create unique abstract paintings and video, ... Get inside a first-person-shooter as it creates action, dialog, ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
Cached News: